{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:30:58Z","timestamp":1792672258460,"version":"4.5.0"},"reference-count":58,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,3,29]],"date-time":"2010-03-29T00:00:00Z","timestamp":1269820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Dean's New Staff Award (SHF)"},{"name":"Cure Parkinson's Trust"},{"name":"Krembil Foundation (JMB)"},{"DOI":"10.13039\/501100003136","name":"Edmond J. Safra Philanthropic Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003136","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000263","name":"Parkinson Society Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000263","id-type":"DOI","asserted-by":"crossref"}]},{"name":"United Kingdom Parkinson's Disease Society Tissue Bank at Imperial College"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2010,7,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Well\u2010formed visual hallucinations (VH) are common in patients with Parkinson's disease (PD). The pathophysiology of VH in PD is unknown but may involve structures mediating visual processing such as the inferior temporal cortex. Serotonergic type 2A (5\u2010HT<jats:sub>2A<\/jats:sub>) receptors have been linked to many psychiatric disorders, including psychosis. We hypothesized that enhanced 5\u2010HT<jats:sub>2A<\/jats:sub> receptor levels may be involved in VH in PD. Autoradiographic binding using [<jats:sup>3<\/jats:sup>H]\u2010ketanserin and spiperone, to define 5\u2010HT<jats:sub>2A<\/jats:sub> receptors, was performed in 6 PD patients with VH, 6 PD patients without VH, and 5 healthy, age\u2010matched controls. The cerebral regions studied included the orbitofrontal cortex, inferolateral temporal cortex, motor cortex, striatum, and substantia nigra. There was a significant (45.6%) increase in the levels of [<jats:sup>3<\/jats:sup>H]\u2010ketanserin binding in the inferolateral temporal cortex of PD patients with VH when compared with PD patients without VH (54.3 \u00b1 5.2 fmol\/mg vs. 37.3 \u00b1 4.3 fmol\/mg, <jats:italic>P<\/jats:italic> = 0.039). Additionally, there was a significant increase in the levels of 5\u2010HT<jats:sub>2A<\/jats:sub> receptors in the motor cortex of all PD patients taken as a group when compared with controls (57.8 \u00b1 5.7 fmol\/mg vs. 41.2 \u00b1 2.6 fmol\/mg, <jats:italic>P<\/jats:italic> = 0.0297). These results suggest that enhanced 5\u2010HT<jats:sub>2A<\/jats:sub>\u2010mediated neurotransmission in the inferolateral temporal cortex, a critical structure in visual processing, might be associated with the development of VH in PD. Our results provide new insights into the pathophysiology of VH in PD and provide an anatomical basis to explain why compounds with 5\u2010HT<jats:sub>2A<\/jats:sub> antagonist activity are effective at alleviating this debilitating complication. \u00a9 2010 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.23083","type":"journal-article","created":{"date-parts":[[2010,3,29]],"date-time":"2010-03-29T15:55:47Z","timestamp":1269878147000},"page":"1399-1408","source":"Crossref","is-referenced-by-count":151,"title":["Increased 5\u2010HT<sub>2A<\/sub> receptors in the temporal cortex of parkinsonian patients with visual hallucinations"],"prefix":"10.1002","volume":"25","author":[{"given":"Philippe","family":"Huot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom H.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayyeba","family":"Darr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili\u2010Naz","family":"Hazrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi P.","family":"Visanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Pires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7,23]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.32.5.514"},{"key":"e_1_2_7_3_2","first-page":"289","article-title":"Poor visual discrimination and visual hallucinations in Parkinson's disease","volume":"21","author":"Diederich NJ","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/123.4.733"},{"key":"e_1_2_7_5_2","first-page":"365","article-title":"Parkinson's disease is a neuropsychiatric disorder","volume":"91","author":"Agid Y","year":"2003","journal-title":"Adv Neurol"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20308"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(05)70146-0"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.2.515"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-004-0209-9"},{"key":"e_1_2_7_10_2","first-page":"461","volume-title":"Psychopharmacology the fourth generation of progress","author":"Jacobs BL","year":"1995"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1099-1077(200008)15:6<397::AID-HUP212>3.0.CO;2-L"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(02)00349-4"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401003"},{"key":"e_1_2_7_14_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1192\/S0007125000296876","article-title":"The importance of serotonin\u2010dopamine interactions in the action of clozapine","author":"Meltzer HY","year":"1992","journal-title":"Br J Psychiatry Suppl"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245606"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn1745"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf033"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.16.8683"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/35086062"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(81)90747-5"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-199501000-00006"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.8.1497"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-895X(25)14623-3"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198706103-00012"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.06.037"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-895X(25)13392-0"},{"key":"e_1_2_7_27_2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0026-895X(25)10354-4","article-title":"3H\u2010DOB (4\u2010bromo\u20102,5\u2010dimethoxyphenylisopropylamine) labels a guanyl nucleotide\u2010sensitive state of cortical 5\u2010HT2 receptors","volume":"31","author":"Lyon RA","year":"1987","journal-title":"Mol Pharmacol"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.17.5.427"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(87)90327-7"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200011)15:6<1064::AID-MDS1002>3.0.CO;2-C"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1123432"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-199111000-00006"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.5.642"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.039867"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp069"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(90)90733-R"},{"key":"e_1_2_7_37_2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0031-6997(25)07220-5","article-title":"Demonstration and mapping of central neurons containing dopamine, noradrenaline, and 5\u2010hydroxytryptamine and their reactions to psychopharmaca","volume":"18","author":"Hillarp NA","year":"1966","journal-title":"Pharmacol Rev"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(71)90178-X"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410220207"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(83)90993-9"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(93)90995-Y"},{"key":"e_1_2_7_42_2","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1523\/JNEUROSCI.16-11-03727.1996","article-title":"Dopamine receptor agonists regulate levels of the serotonin 5\u2010HT2A receptor and its mRNA in a subpopulation of rat striatal neurons","volume":"16","author":"Laprade N","year":"1996","journal-title":"J Neurosci"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.10.4708"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/syn.10273"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0606578103"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm082"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(08)00922-9"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21475"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(92)90344-8"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0193(1999)7:1<29::AID-HBM3>3.0.CO;2-R"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn1333"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(04)00070-4"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-0885-8"},{"issue":"1","key":"e_1_2_7_54_2","first-page":"S75","article-title":"Investigating 5HT2A receptor binding in PD patients with visual hallucinations: a [18F]setoperone PET study","volume":"23","author":"Ballanger B","year":"2008","journal-title":"Mov Disord"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0173(94)00007-C"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.066365"},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-1887-6"},{"key":"e_1_2_7_58_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-27-09107.2003"},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000110317.52453.6C"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.23083","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.23083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:59:25Z","timestamp":1760954365000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.23083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,23]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,7,30]]}},"alternative-id":["10.1002\/mds.23083"],"URL":"https:\/\/doi.org\/10.1002\/mds.23083","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,23]]}}}